Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Go back to Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma| (NASDAQ: LEGN) | Delayed: 23.53 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $23.53 | 52 Week High | $ | |||
| Open | $23.31 | 52 Week Low | $ | |||
| Day High | $24.05 | P/E | N/A | |||
| Day Low | $23.16 | EPS | $ | |||
| Volume | 943,630 | |||||
